Lipocine Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2022; filed November 9, 2022. Lipocine is a clinical-stage biopharmaceutical company developing oral drug-delivery products. Its TLANDO product was FDA-approved in March 2022 and launched by licensee Antares in June 2022; the company reported no product-sale revenue.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $55,000 | $500,000 | $55,000 |
| Research and development | $2.10 million | $2.37 million | $6.89 million | $5.41 million |
| General and administrative | $799,000 | $1.22 million | $3.17 million | $4.28 million |
| Operating loss | $2.90 million | $3.53 million | $9.56 million | $9.64 million |
| Net loss | $2.41 million | $3.08 million | $8.53 million | $13.26 million |
| Basic loss per share | $0.03 | $0.03 | $0.10 | $0.15 |
Margins: Not meaningful given negligible revenue and continuing operating losses.
- Cash and liquidity: At September 30, cash and cash equivalents were $2.40 million and marketable securities were $31.86 million. Management reported $34.3 million of unrestricted cash, cash equivalents, and marketable securities, versus $46.6 million at year-end 2021. Current assets were $36.11 million; current liabilities were $1.51 million.
- Cash flow: Nine-month operating cash use was $10.13 million, compared with $13.41 million in 2021. Investing activities provided $11.70 million, primarily from security maturities; financing activities used $2.12 million, primarily for debt repayment and the final loan payment.
- Debt: The Silicon Valley Bank loan was paid in full at maturity in June 2022, including a $650,000 final payment charge. No debt was reported at September 30.
- Balance sheet: Total assets were $39.42 million, total liabilities $1.78 million, and stockholders’ equity $37.65 million. Accumulated deficit was $181.2 million.
Material changes versus the comparable period
- Nine-month net loss improved by $4.73 million year over year, largely because 2021 included a $4.0 million Clarus litigation settlement expense. The 2022 period instead included a $250,000 settlement-related gain.
- Nine-month R&D expense increased $1.47 million, primarily reflecting LPCN 1148 Phase 2 study costs, LPCN 1154 clinical work, and LPCN 1111 manufacturing scale-up; these increases were partly offset by completion of the LPCN 1144 LiFT Phase 2 study.
- Nine-month G&A expense declined $1.11 million, mainly due to lower legal costs than in 2021, partly offset by professional, consulting, and other costs.
- Nine-month revenue was $500,000, consisting of a non-refundable Antares fee for extending its LPCN 1111 option. Antares did not exercise that option, which expired June 30, 2022. The $55,000 recognized in 2021 came from Spriaso licensing payments.
- Rising interest rates increased interest and investment income. A non-cash gain from revaluing warrant liabilities was recorded in both periods and affected reported earnings.
Outlook, developments, and risks
- Management said existing capital resources were expected to fund projected operations through at least September 30, 2023, including planned clinical work and regulatory compliance. The estimate depends on assumptions; management expects to need additional capital thereafter and warns that additional studies or other changes could accelerate cash use. Failure to raise funds could threaten continuation as a going concern.
- LPCN 1154: a pilot pharmacokinetic bridge study for postpartum depression was underway; results were expected in the first half of 2023. LPCN 1148: enrollment in its Phase 2 cirrhosis study was expected to complete in Q4 2022, with 24-week topline results expected in the first half of 2023. LPCN 2101’s IND was accepted, and a Phase 2 study was planned for 2023 subject to available resources.
- The company was seeking partners for LPCN 1144, LPCN 1148, LPCN 1111, LPCN 1107, and ex-U.S. TLANDO; it cautioned that agreements may not be secured or favorable. FDA feedback for LPCN 1144 included recommending a dose-ranging study before a pivotal study.
- Antares, acquired by Halozyme in May 2022, is responsible for U.S. TLANDO commercialization and required post-marketing work under the license. Lipocine estimated no royalty payment on Antares’ third-quarter 2022 TLANDO sales. The company remains eligible for tiered royalties and up to $160 million in sales milestones, subject to agreement terms and achievement.
- The Clarus patent litigation and related interference were resolved under a settlement; the amended terms reduced future payments by $250,000, and no future royalties are due. A separate shareholder class action remained pending; management had not accrued a loss because it did not consider an outcome probable or estimable.
- Nasdaq notified the company in June 2022 that its share price had been below the $1 minimum bid price for 30 consecutive business days. The compliance period ran through December 5, 2022; the company said it would monitor compliance and consider options, including a reverse split.
- Disclosure controls were reported effective as of September 30, 2022, with no material change in internal control over financial reporting during the quarter.
Investor verification priorities
- Check subsequent filings for actual cash burn, financing, and whether management’s stated runway through September 2023 remained achievable.
- Review LPCN 1154 and LPCN 1148 study progress and results, and whether LPCN 2101’s planned study proceeded.
- Monitor TLANDO sales and resulting royalties, any milestone eligibility, and the impact of Antares’ third-quarter sales estimate.
- Confirm Nasdaq bid-price compliance after the December 5, 2022 deadline and any related listing actions.
- Track the shareholder class action, remaining contractual commitments, and possible dilution from future equity financing or the available ATM facility.